In Vivo Antiarrhythmic Profile of AP-792 Assessed in Different Canine Arrhythmia Models.

DOI Web Site Web Site Web Site PubMed 被引用文献1件 参考文献30件

この論文をさがす

抄録

The antiarrhythmic effects of a novel antiarrhythmic drug AP-792, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-cyclohexylbutyl]piperidine hydrochloride, were analyzed using the epinephrine-, digitalis-and two-stage coronary ligation-induced canine ventricular arrhythmia models. Intravenous administration of AP-792 (0.3 or 1.0 mg/kg) effectively suppressed each of the ventricular arrhythmias, an action that resembles that of a typical cardioselective Ca2+ channel blocker, AH-1058. The antiarrhythmic action of AP-792 was slow in onset and longer-lasting than those in our previous studies using more than 50 antiarrhythmic drugs, including Na+ and Ca2+ channel blockers. These results suggest that AP-792 can become a unique long-acting antiarrhythmic drug.

収録刊行物

  • Jpn.J.Pharmacol.

    Jpn.J.Pharmacol. 87 (1), 21-26, 2001

    公益社団法人 日本薬理学会

被引用文献 (1)*注記

もっと見る

参考文献 (30)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ